PUBLICATION

Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery

Authors
Morgan, E., Gamble, J.T., Pearce, M.C., Elson, D.J., Tanguay, R.L., Kolluri, S.K., Reich, N.O.
ID
ZDB-PUB-200506-18
Date
2019
Source
Apoptosis : an international journal on programmed cell death   24: 529-537 (Journal)
Registered Authors
Tanguay, Robyn L.
Keywords
Apoptosis, Bcl-2, Hollow gold nanoshells, NuBCP, Peptide delivery, Resistant cancer
MeSH Terms
  • Animals
  • Antineoplastic Agents/chemistry*
  • Antineoplastic Agents/pharmacology
  • Apoptosis/drug effects
  • Cell Line, Tumor
  • Cell Survival/drug effects
  • Drug Carriers/chemistry
  • Drug Carriers/pharmacology
  • Drug Delivery Systems*
  • Drug Liberation
  • Drug Resistance, Neoplasm/drug effects
  • Gold/chemistry*
  • Humans
  • Laser Therapy
  • Lung Neoplasms/metabolism
  • Lung Neoplasms/pathology
  • Lung Neoplasms/therapy
  • Nanoshells/chemistry*
  • Oligopeptides/chemistry
  • Oligopeptides/pharmacology
  • Paclitaxel/pharmacology
  • Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors
  • Proto-Oncogene Proteins c-bcl-2/metabolism*
  • Xenograft Model Antitumor Assays
  • Zebrafish/growth & development
  • Zebrafish/physiology
PubMed
30879165 Full text @ Apoptosis
Abstract
Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping